错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

MR perfusion characteristics of pseudoprogression in brain tumors treated with immunotherapy – a comparative study with chemo-radiation induced pseudoprogression and radiation necrosis

  • Hongyan Chen,
  • Guirong Tan,
  • Lijuan Zhong,
  • Yichuan Hu,
  • Wenjing Han,
  • Yi Huang,
  • Qiong Liang,
  • Denes Szekeres,
  • Haihui Jiang,
  • Rajnish Bharadwaj,
  • Stephen M. Smith,
  • Henry Z. Wang,
  • Xiang Liu

摘要

Purpose

Pseudoprogression is an atypical imaging pattern of response to immunotherapy in patients with brain tumors. MR perfusion studies in this field are limited. The purpose of our study is to compare the perfusion features between pseudoprogression lesions in malignant gliomas and brain metastases treated with immunotherapy (iPsP) and the pseudoprogression after chemo-radiation therapy and radiation necrosis after radiation treatment (ChR-PsP & RN).

Methods

We retrospectively reviewed 25 iPsP lesions in 16 brain tumor patients and 48 ChR-PsP & RN lesions in 35 patients. The cerebral blood volume (CBV) of MR dynamic susceptibility contrast (DSC) perfusion weighted imaging (PWI) was analyzed, and the mean and maximal values of the ratio of CBV (rCBVmean and rCBVmax) of iPsPs and ChR-PsP & RNs were calculated and compared between these two groups using the Mann-Whitney U test. A receiver operating characteristic curve analysis was conducted, and the optimal cutoff of perfusion parameters were determined using the area under the curve, sensitivity, and specificity.

Results

The medians of rCBVmean and rCBVmax in iPsP group were significantly higher (0.94 and 1.39 respectively) than ChR-PsP & RN group (0.67, p < 0.01 and 1.1, p = 0.01 respectively). The rCBVmean value of 0.69 can differentiate the iPsP from ChR-PsP & RN with the area under the curve of 0.71, sensitivity of 0.72, and specificity of 0.56.

Conclusion

These findings may suggest immunotherapy-induced higher perfusion in the iPsP lesions compared to ChR-PsP & RN lesions in primary and metastatic brain tumors.